Literature DB >> 24799830

Lorcaserin: A novel antiobesity drug.

Dick B S Brashier1, A K Sharma1, Navdeep Dahiya1, S K Singh1, Anjan Khadka1.   

Abstract

Obesity is a major co-morbidity with hypertension and diabetes mellitus. There are few drugs for treatment of obesity like orlistat and recentlty approved drug lorcaserin. Lorcaserin has serotonergic properties and acts as an anorectic. It may cause serious side effects, including serotonin syndrome, particularly when taken with certain medicines that increase serotonin levels or activate serotonin receptors. Although, mainstay and first line of approach of treatment will always remain in having low calorie diet and increase in physical activity. Lorcaserin has come as a new hope to achieve success in treating obese patients but still a long road with further extensive research to be undertaken in the treatment of obesity.

Entities:  

Keywords:  Lorcaserin; obesity; serotonin

Year:  2014        PMID: 24799830      PMCID: PMC4008925          DOI: 10.4103/0976-500X.130158

Source DB:  PubMed          Journal:  J Pharmacol Pharmacother        ISSN: 0976-500X


  15 in total

1.  Lorcaserin--not a new weapon in the battle with appetite.

Authors:  Jason C G Halford
Journal:  Nat Rev Endocrinol       Date:  2010-12       Impact factor: 43.330

2.  Multicenter, placebo-controlled trial of lorcaserin for weight management.

Authors:  Steven R Smith; Neil J Weissman; Christen M Anderson; Matilde Sanchez; Emil Chuang; Scott Stubbe; Harold Bays; William R Shanahan
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 3.  Lorcaserin: an investigational serotonin 2C agonist for weight loss.

Authors:  Kathryn M Hurren; Helen D Berlie
Journal:  Am J Health Syst Pharm       Date:  2011-11-01       Impact factor: 2.637

4.  Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.

Authors:  Patrick M O'Neil; Steven R Smith; Neil J Weissman; Meredith C Fidler; Matilde Sanchez; Jinkun Zhang; Brian Raether; Christen M Anderson; William R Shanahan
Journal:  Obesity (Silver Spring)       Date:  2012-03-16       Impact factor: 5.002

Review 5.  Recent advancements in drug treatment of obesity.

Authors:  Rebeca Carter; Angelina Mouralidarane; Shuvra Ray; Junpei Soeda; Jude Oben
Journal:  Clin Med (Lond)       Date:  2012-10       Impact factor: 2.659

6.  Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users.

Authors:  M J Shram; K A Schoedel; C Bartlett; R L Shazer; C M Anderson; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  2011-03-16       Impact factor: 6.875

7.  A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.

Authors:  Meredith C Fidler; Matilde Sanchez; Brian Raether; Neil J Weissman; Steven R Smith; William R Shanahan; Christen M Anderson
Journal:  J Clin Endocrinol Metab       Date:  2011-07-27       Impact factor: 5.958

Review 8.  Lorcaserin for the treatment of obesity.

Authors:  L M Redman; E Ravussin
Journal:  Drugs Today (Barc)       Date:  2010-12       Impact factor: 2.245

Review 9.  Global burden of obesity in 2005 and projections to 2030.

Authors:  T Kelly; W Yang; C-S Chen; K Reynolds; J He
Journal:  Int J Obes (Lond)       Date:  2008-07-08       Impact factor: 5.095

10.  Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.

Authors:  William J Thomsen; Andrew J Grottick; Frederique Menzaghi; Hazel Reyes-Saldana; Stephen Espitia; Diane Yuskin; Kevin Whelan; Michael Martin; Michael Morgan; Weichao Chen; Hussien Al-Shamma; Brian Smith; Derek Chalmers; Dominic Behan
Journal:  J Pharmacol Exp Ther       Date:  2008-02-05       Impact factor: 4.030

View more
  8 in total

Review 1.  Fatty liver disease in diabetes mellitus.

Authors:  Harikrashna B Bhatt; Robert J Smith
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

Review 2.  Pharmacological treatment and therapeutic perspectives of metabolic syndrome.

Authors:  Soo Lim; Robert H Eckel
Journal:  Rev Endocr Metab Disord       Date:  2014-12       Impact factor: 6.514

3.  Novel Natural Oximes and Oxime Esters with a Vibralactone Backbone from the Basidiomycete Boreostereum vibrans.

Authors:  He-Ping Chen; Zhen-Zhu Zhao; Zheng-Hui Li; Ze-Jun Dong; Kun Wei; Xue Bai; Ling Zhang; Chun-Nan Wen; Tao Feng; Ji-Kai Liu
Journal:  ChemistryOpen       Date:  2016-01-13       Impact factor: 2.911

4.  Inhibition of glycine transporter-1 in the dorsal vagal complex improves metabolic homeostasis in diabetes and obesity.

Authors:  Jessica T Y Yue; Mona A Abraham; Paige V Bauer; Mary P LaPierre; Peili Wang; Frank A Duca; Beatrice M Filippi; Owen Chan; Tony K T Lam
Journal:  Nat Commun       Date:  2016-11-22       Impact factor: 14.919

5.  The Combination of Ephedrae herba and Coicis semen in Gambihwan Attenuates Obesity and Metabolic Syndrome in High-Fat Diet-Induced Obese Mice.

Authors:  Jun-Woo Jang; Dong-Woo Lim; Ji-Ung Chang; Jai-Eun Kim
Journal:  Evid Based Complement Alternat Med       Date:  2018-08-19       Impact factor: 2.629

6.  Lorcaserin for prevention and remission of type 2 diabetes mellitus in people with overweight or obesity: protocol for a systematic review and meta-analysis.

Authors:  Hai Zeng; Meng Luo; Zunjiang Li; Junru Wen; Guoxin He; Yuelin Jin; Wenbin Fu; Peng Zhou
Journal:  BMJ Open       Date:  2019-07-27       Impact factor: 2.692

7.  Pharmacological interventions for obesity: current and future targets.

Authors:  Miriam E Bocarsly
Journal:  Curr Addict Rep       Date:  2018-05-07

8.  A selective serotonin receptor agonist for weight loss and management of menopausal vasomotor symptoms in overweight midlife women: a pilot study.

Authors:  Ekta Kapoor; Stephanie Faubion; Ryan T Hurt; Karen Fischer; Darrell Schroeder; Shawn Fokken; Ivana T Croghan
Journal:  Menopause       Date:  2020-11       Impact factor: 3.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.